Researchers at University of Tsukuba have identified multiple T-cell subtypes with unique characteristics in follicular ...

Researchers at University of Tsukuba have identified multiple T-cell subtypes with unique characteristics in follicular lymphoma, a prevalent type of blood cancer. These T cells regulate the ...

Follicular lymphoma can develop into a faster-growing form known as diffuse large B-cell lymphoma. Transformed lymphoma is usually more aggressive and may require more rigorous treatment.

SGN-CD19A demonstrated anti-tumor activity across a panel of cell lines derived from multiple B-cell lymphoma and leukemia subtypes. [53] ...

Monjuvi added to Rituxan and Revlimid extended progression-free survival from 14 to 22 months in follicular lymphoma, ...

The inMIND trial led to the FDA approval of Monjuvi with Revlimid and Rituxan for relapsed follicular lymphoma, showing benefits across diverse patients.

Mantle cell lymphoma treatment offers options if patients relapse after CAR T-cell therapy, from bispecific antibodies, antibody drug conjugates, and other emerging therapies.

Why You Might Get a Relapse After your treatment for follicular lymphoma, some cancer cells could have been left behind. There may have been too few for any scans or tests to see them.

The FDA has declined to approve Columvi, in combination with the chemo regimen GemOx, for the treatment of second-line DLBCL ...

The study aims to evaluate the safety and efficacy of odronextamab compared to rituximab combined with chemotherapy in treating follicular lymphoma, a type of non-Hodgkin lymphoma.

A research team has discovered a previously unknown mechanism that could explain why many patients with aggressive B-cell lymphoma do not respond to CAR-T cell therapy in the long term. The ...